Additionally, while multiple genomic and non-genomic factors have been associated with resistance to KRAS inhibitors, such as co-mutations of KEAP1/STK11 with KRAS as observed in patients with lung cancer, KEAP1/STK11 co-mutations are rare in pancreatic cancer, and little is known about the landscape of KRAS mutations and co-mutations in pancreatic cancer or their impact on clinical outcomes12,24,25. This evidence concerns the gene KEAP1 and familial pancreatic carcinoma.